RLMD Stock, Relmada Therapeutics Inc. Information

Relmada Therapeutics is a clinical stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system CNS diseases. The Company has a diversified portfolio of four products at various stages of development, including d Methadone dextromethadone, REL , an N methyl D aspartate NMDA receptor antagonist for depression and neuropathic pain LevoCap ER REL , an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine BuTab, REL , an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine MepiGel, REL , an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company s product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.